skip to content
Long-Term Consequences of Drugs on the Paediatric Cardiovascular System
ClosePreview this item
Checking...

Long-Term Consequences of Drugs on the Paediatric Cardiovascular System

Author: Elizabeth HausnerMonica FiszmanJoseph HanigPatricia HarlowGwen ZornbergAll authors
Publisher: Adis International Limited
Edition/Format: Article Article : English
Publication:Drug Safety, 31, no. 12 (2008): 1083-1096
Database:ArticleFirst
Other Databases: MEDLINEElsevierBritish Library Serials
Rating:

(not yet rated) 0 with reviews - Be the first.

More like this

 

&AllPage.SpinnerRetrieving;

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Document Type: Article
All Authors / Contributors: Elizabeth Hausner; Monica Fiszman; Joseph Hanig; Patricia Harlow; Gwen Zornberg; Solomon Sobel
ISSN:0114-5916
Language Note: English
Unique Identifier: 365863444
Awards:

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

All user tags (1)

View most popular tags as: tag list | tag cloud

  • good  (by 1 person)

Similar Items

User lists with this item (1)

Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


<http://www.worldcat.org/oclc/365863444>
library:oclcnum"365863444"
owl:sameAs<info:oclcnum/365863444>
rdf:typeschema:Article
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2008-12-11"
schema:description"Many pharmacological and toxicological actions of drugs in children cannot be fully predicted from adult clinical experience or from standard non-clinical toxicology studies. Numerous drugs have direct or indirect pharmacological effects on the heart and are prescribed for children of all ages. Toxicity or secondary effects may be immediate or delayed for years after drug exposure has ceased. Originally, the aim of this review was to compile information on the effect of specific drugs on the post-natal development of the cardiovascular system and to examine long-term follow-up of the use of cardio-active drugs in children. The limited database of published information caused the original question to evolve into an examination of the medical literature for three areas of information: (i) whether vulnerable developmental windows have been identified that reflect the substantial functional development that the cardiovascular system undergoes after birth; (ii) what is known about pharmacological perturbation of development; and (iii) what the likelihood is of drug exposure during childhood. We examined different scenarios for exposure including random, isolated exposure, conditions historically associated with adults, primary or secondary cardiac disease, psychiatric and neurological conditions, asthma, cancer and HIV. Except for random, isolated drug exposures, each category of possible exposure contained numerous drugs known to have either primary or secondary effects on the cardiovascular system or to influence factors associated with atherosclerosis. It is likely that a significant number of children will be prescribed drugs having either direct or indirect effects upon the immature cardiovascular system. A confounding factor is the simultaneous use of over-the-counter medications and herbal or nutraceutical preparations that a patient, parent or guardian does not mention to a prescribing physician. Metabolism is also important in assessing drug effects in children. Differences in body water : body fat ratio, age-related gastrointestinal absorption, distribution, excretion, renal function and drug metabolizing capabilities make it possible for children to have a different metabolite profile for a drug compared with adults. There is little examination of drug effects on the interdependent processes of cardiac maturation and less examination of metabolite effects. It is difficult to identify delayed toxicities in children as these adverse events may take years to manifest with many patients lost to follow-up. Clearly this is an area of study where intermediate endpoints and surrogate markers would be of great benefit. Pharmacogenomics may be useful in providing markers of increased risk or susceptibility. A perspective must be kept in balancing the possibility of a problem with the very real benefits that many children experience from the use of these pharmaceuticals."
schema:exampleOfWork<http://worldcat.org/entity/work/id/159255745>
schema:inLanguage"en"
schema:isPartOf
schema:name"Long-Term Consequences of Drugs on the Paediatric Cardiovascular System"
schema:pageStart"1083"
schema:publisher
schema:url

Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.